Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC4 | P56524 | 8/20 | 0.43 |
| ▸ | HDAC6 | Q9UBN7 | 7/20 | 0.43 |
| ▸ | HDAC1 | Q13547 | 3/20 | 0.43 |
| ▸ | GCGR | P47871 | 1/20 | 0.42 |
| ▸ | GIPR | P48546 | 1/20 | 0.42 |
| ▸ | KIFC1 | Q9BW19 | 5/20 | 0.42 |
| ▸ | RHOC | P08134 | 1/20 | 0.41 |
| ▸ | RHOA | P61586 | 1/20 | 0.41 |
| ▸ | SIRT5 | Q9NXA8 | 1/20 | 0.41 |
| ▸ | S1PR1 | P21453 | 2/20 | 0.41 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30497205 | 1.00 | HDAC4 (0.43) | HDAC4HDAC6HDAC1GCGRGIPR | |
| SCHEMBL25295021 | 0.83 | FABP4 (0.50) | GCGRGIPRKIFC1SIRT5 | |
| SCHEMBL30497244 | 0.83 | FABP4 (0.50) | GCGRGIPRKIFC1SIRT5 | |
| SCHEMBL30497176 | 0.81 | RXRA (0.44) | S1PR1 | |
| SCHEMBL25301433 | 0.81 | RXRA (0.44) | S1PR1 | |
| SCHEMBL25254573 | 0.80 | KIFC1 (0.60) | HDAC6HDAC1KIFC1S1PR1 | |
| SCHEMBL30497131 | 0.80 | KIFC1 (0.60) | HDAC6HDAC1KIFC1S1PR1 | |
| SCHEMBL1534290 | 0.78 | RHOC (0.59) | GCGRGIPRRHOCRHOARXFP1 | |
| SCHEMBL12959472 | 0.77 | RHOC (0.50) | GCGRGIPRRHOCRHOARXFP1 | |
| SCHEMBL25251606 | 0.76 | KIFC1 (0.76) | KIFC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250084074-A1 | SUBSTITUTED HETEROCYCLES AS HSET INHIBITORS | MERCK PATENT GMBH (DE) | 2025-03-13 | — | — | US | disclosed |
| WO-2023131690-A1 | SUBSTITUTED HETEROCYCLES AS HSET INHIBITORS | MERCK PATENT GMBH (DE) | 2023-07-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250084074-A1 | SUBSTITUTED HETEROCYCLES AS HSET INHIBITORS | VHL, CDKN1A, CCNI | HDAC4 465/4885HDAC6 494/4885HDAC1 119/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.